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Abstract
Background: It is long known within the mathematical literature that the coefficient of determination R2 is an 
inadequate measure for the goodness of fit in nonlinear models. Nevertheless, it is still frequently used within 
pharmacological and biochemical literature for the analysis and interpretation of nonlinear fitting to data.
Results: The intensive simulation approach undermines previous observations and emphasizes the extremely low 
performance of R2 as a basis for model validity and performance when applied to pharmacological/biochemical 
nonlinear data. In fact, with the 'true' model having up to 500 times more strength of evidence based on Akaike 
weights, this was only reflected in the third to fifth decimal place of R2. In addition, even the bias-corrected R2
adj 
exhibited an extreme bias to higher parametrized models. The bias-corrected AICc and also BIC performed significantly 
better in this respect.
Conclusion: Researchers and reviewers should be aware that R2 is inappropriate when used for demonstrating the 
performance or validity of a certain nonlinear model. It should ideally be removed from scientific literature dealing with 
nonlinear model fitting or at least be supplemented with other methods such as AIC or BIC or used in context to other 
models in question.
Background
Fitting nonlinear models to data is frequently applied
within all fields of pharmaceutical and biochemical assay
quantification. A plethora of nonlinear models exist, and
chosing the right model for the data at hand is a mixture
of experience, knowledge about the underlying process
and statistical interpretation of the fitting outcome.
While the former are of somewhat individual nature,
there is a need in quantifying the validity of a fit by some
measure which discriminates a 'good' from a 'bad' fit. The
most common measure is the coefficient of determina-
tion R2 used in linear regression when conducting cali-
bration experiments for samples to be quantified [1]. In
the linear context, this measure is very intuitive as values
between 0 and 1 give a quick interpretation of how much
o f  t h e  v a r i a n c e  i n  t h e  d a t a  i s  e x p l a i n e d  b y  t h e  f i t .
Although it is known now for some time that R 2 is an
inadequate measure for nonlinear regression, many sci-
entists and also reviewers insist on it being supplied in
papers dealing with nonlinear data analysis. Several initial
and older descriptions for R2 being of no avail in nonlin-
ear fitting had pointed out this issue but have probably
fallen into oblivion [2-8]. This observation might be due
to differences in the mathematical background of trained
statisticians and biochemists/pharmacologists who often
apply statistical methods but lack detailed statistical
insight.
We made the observation that R2  is still frequently
being used in the context of performance or validity of a
certain model when fit to nonlinear data. R2 is not an
optimal choice in a nonlinear regime as the the total sum-
of-squares (TSS) is not equal to the regression sum-of-
squares (REGSS) plus the residual sum-of-squares (RSS),
as is the case in linear regression, and hence it lacks the
above interpretation (see Additional File 1, paragraphs 1
& 2). To our observation, there is still a high occurrence
in the present literature of all biomedical fields where the
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validity of nonlinear models is based solely on R2 values,
which might be a result of authors or reviewers not being
aware of this fallacy. Additionally, almost all of the com-
mercially available statistical software packages (i.e.
Prism, Origin, Matlab, SPSS, SAS) calculate R2 values for
nonlinear fits, which is bound to unintentionally corrobo-
rate its frequent use. A further example is the
TableCurve2 D software (Systat, USA) which can fit hun-
dreds of nonlinear models to a given dataset automati-
cally and then rank these by means of R2. Noted 25 years
ago by Kvalseth [8], the user is usually not able to identify
which of the eight different definitions of R2 that are com-
monly being used in the literature is chosen for the analy-
sis output in statistical software (see Additional File 1,
Remark 4).
We thus aimed to point out the low performance of R2
and its inappropriateness for nonlinear data analysis by
basing our analysis on an extensive Monte Carlo simula-
tion approach. This approach has fundamental advan-
tages in the analysis of nonlinear data analysis [9] and can
reveal tendencies within statistical methods by supplying
the models and measures in question with thousands of
generated datasets.
Methods
Creation of the 'true' model
In a first step, we fitted a three-parameter log-logistic
model (L3, see Formula 3 below) by nonlinear least-
squares to sigmoidal data that was taken from quantita-
tive real-time polymerase chain reaction (qPCR). This
yielded a sigmoidal model with the parameters b = -9.90,
d = 11.07 and e = 24.75. We used the fitted values of this
model and x-values from 10-35 as the 'true' model with
sample size n = 26 for the following Monte Carlo simula-
tion. This essentially gave a sigmoidal curve that can be
encountered in many different areas of pharmacological/
biochemical analysis. Specific to qPCR data, the x-values
("Cycles") are equidistant and not on a log-scale, as often
encountered in dose-response analysis. For mathematical
details, see Remark 7 in Additional File 1.
Perturbation of data (Monte Carlo Simulation)
Using the fitted values as above, all datapoints were per-
turbed 2000 times by adding six different magnitudes
(very low to high) of homoscedastic noise from a gaussian
distribution with mean = 0 and standard deviations =
0.01, 0.02, 0.05, 0.1, 0.2 or 0.4. The noise of the data was
therefore between 0.1% and 4% of the data range. This
way, for each of six different settings (determined by dif-
ferent standard deviations), we obtained 2000 new data
sets of sample size n = 26 with true model L3. For each of
these data sets, nine different sigmoidal models differing
in model type and number of parameters (Formulas 1-9)
were fit. For mathematical details, see Remark 7 in Addi-
tional File 1.
Formula 1: Five parameter log-logistic model (L5):
Formula 2: Four-parameter log-logistic model (L4):
Formula 3: Three-parameter log-logistic model (L3):
Formula 4: Five parameter logistic model (B5):
Formula 5: Four-parameter logistic model (B4):
Formula 6: Three-parameter logistic model (B3):
Formula 7: Four-parameter Weibull model (W4):
Formula 8: Three-parameter Weibull model (W3):
Formula 9: Five-parameter baroreflex model (baro5):
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Calculation of measures for goodness-of-fit
For each simulation, we calculated the following mea-
sures for goodness-of-fit:
R2, using the most general definition [5,8]:
Formula 10:
with RSS = residual sum-of-squares, TSS = total sum-
of-squares, y = response values,   = fitted values and   =
the mean of response values. For a more detailed descrip-
tion see Remarks 1-6 in Additional File 1.
We chose to use the adjusted R2 to compensate for pos-
sible bias due to different number of parameters:
Formula 11:
with n = sample size and p = number of parameters.
The Akaike Information Criterion (AIC, [10-12]), a
measure that is widely accepted for measuring the valid-
ity within a cohort of nonlinear models and frequently
used for model selection [13].
Formula 12:
with p = number of parameters and ln(L) = maximum
log-likelihood of the estimated model. The latter, in the
case of a nonlinear fit with normally distributed errors
[13], is calculated by
Formula 13:
with x1, ..., xn = the residuals from the nonlinear least-
squares fit and N = their number.
To provide a fair playing ground, we employed an AIC
variant that corrects for small sample sizes, the bias-cor-
rected AIC (AICc):
Formula 14:
with n = sample size and p = number of parameters.
In order to obtain values for the validity of a fit, we used
Akaike weights which calculate the weight of evidence for
each model within a cohort of models in question [12-
14]:
Formula 15:
with i, k = model numbers, Δi(AIC) = the difference in
AIC of each model in comparison to the model with the
lowest AIC, subsequently normalized to their sum
(denominator).
Also here, we used the bias-corrected AICc for calcu-
lating the Akaike weights.
We also chose to employ the Bayesian Information Cri-
terion (BIC), which gives a higher penalty on the number
of parameters [15]:
Formula 16:
with p = number of parameters, n = sample size and L =
maximum likelihood of the estimated model.
Furthermore, the residual variance as the part of the
variance that cannot be accounted for by the model:
Formula 17:
with RSS = residual sum-of-squares, n = sample size
and p = number of parameters.
The variance of a least-squares fit is also characterized
by the chi-square statistic defined as Formula 18:
where yi = response values, f(xi) = the fitted values and
 = the uncertainty in the individual measurements yi.
We further define the reduced chi-square as a useful
measure [16] by
Formula 19:
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with ν = n - p (degrees of freedom). If the fitting func-
tion is a good approximation to the parent function, then
the variances of both should agree well, and the reduced
chi-square should be approximately unity. If the reduced
chi-square is much larger than 1 (i.e. 10 or 100), it means
that one is either overly optimistic about the measure-
ment errors or that one selected an inappropriate fitting
function. If reduced chi-square is too small (i.e. 0.1 or
0.01) it may mean that one has been too pessimistic about
measurement errors. For this work, models were selected
based on reduced chi-square by being closest to 1.
Analysis of the simulation data
Two different approaches were pursued within the Monte
Carlo simulated data. To reveal general tendencies, we
averaged the values of R2
adj, AICc, BIC, residual variance
and reduced chi-square from all 2000 simulated data sets
(for each noise magnitude and each of the 9 models). To
permit a more detailed insight for each simulation and to
compare the measures on the single model level, we
selected the best model in each iteration based on the
highest R2
adj, lowest AICc, lowest BIC, lowest residual
variance and smallest difference to unity for reduced chi-
square. For the latter, we used as the measurement uncer-
tainty   the  a priori known squared standard deviation
from the homoscedastic noise that was applied to pro-
duce the random data of the Monte Carlo simulations.
F inally , we calcula ted the perc en tage of se lecting the
'true' model L3 in all iterations.
Code for the simulations
All simulations were conducted using R, a well reputed
and open-source statistical programming language [17].
Nonlinear curve fitting was done by using functionality
from the R package qpcR [18]. The commented code for
the simulations can be obtained from Additional File 2.
Results and Discussion
Figure 1 illustrates the simulated data that was used as the
basis of our analysis. Starting from the fitted values of a
three-parameter log-logistic model (L3), different
amounts of homoscedastic gaussian noise were added to
the fitted values resulting in the point clouds as shown.
We analyzed six different magnitudes of gaussian noise in
total, from low noise (s.d. = 0.01, 0.02), medium noise
(s.d. = 0.05, 0.1) to high noise (s.d. = 0.2, 0.4; see Figure 1)
with a total of 2000 simulations per noise setup.
Fitting all nine different sigmoidal models to the fitted
values of the 'true' model (L3) is depicted in Figure 2A,
demonstrating the differences against this model when
noise is completely lacking. All logistic models fit well in
this context, which tallies with the observation of five-
parameter models exhibiting increased performance due
to accomodating asymmetrical structures [19]. Visualized
also by a residuals plot that delivers higher resolution of
the residuals (Figure 2B), the log-logistic models (L3, L4,
L5) provide very small residual values, the logistic models
(B3, B4, B5) have higher residual values and the Weibull
models (W3, W4) are significantly inferior. This is evi-
dent especially in the upper and lower region from the
point of inflection.
AICc and adjusted R2
adj were compared by averaging
the output of all 2000 simulations and for three different
magnitudes (low, middle, high) of homoscedastic gauss-
ian noise (Figure 3). Not surprisingly, the R2
adj values
decrease and the AICc values increase with higher noise
(left to right). But the major problem in the use of R2 is
clearly evident within the simulation setup: the AIC dif-
ferences (delta-AIC) between some models can be 78
(compare L3 and B3 models at s.d. = 0.02), which when
transferred to Akaike weights result in a weight of evi-
dence 16 (!) orders of magnitude in favor of L3. One might
be inclined to say that this is major evidence for the first
model being in favor of the second one, but in respect to
the corresponding R2
adj values, only the fourth decimal
place is affected. This tendency is also found for higher
noise, despite AICc values increasing and R2
adj values
s i
2
Figure 1 Graph illustrating the noise model used for the simula-
tions. 2000 simulations of random gaussian noise with mean = 0 and 
s.d. = 0.4 were added to the fitted values of a three-parameter log-lo-
gistic model (L3) fit to real-time quantitative PCR data. This resulted in 
the point cloud (black dots) of response values and the band of red 
lines reflecting the fitted curves of all simulations with the same model 
L3 applied.
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Figure 2 Performance of the nine different sigmoidal models on the fitted values from a three-parameter log-logistic model. (A) The nine 
different sigmoidal models were fit by nonlinear least-squares to the fitted data from the L3 model. (B) Residual plot depicting the performance of 
each of the nine models in respect to fitting to the data from the L3 model. As expected, model L3 (light green, reference curve) has zero residual 
value as having been fit to the data obtained from the same model. Several other models also fit the data exceptionally well (L5, L4, baro5) and are 
not visible due to being overlayed by the L3 curve. Descriptions for the abbreviated models can be found under Formulas 1-9.
A
B
Cycles
r
a
w
f
l
u
o
r
e
s
c
e
n
c
e
r
e
s
i
d
i
d
u
a
l
v
a
l
u
e
0
2
4
6
8
1
0
L5
L4
L3
B5
B4
B3
W4
W3
baro5
10 15 20 25 30 35
-
0
.
3
-
0
.
2
-
0
.
1
0
.
0
0
.
1
0
.
2
0
.
3Spiess and Neumeyer BMC Pharmacology 2010, 10:6
http://www.biomedcentral.com/1471-2210/10/6
Page 6 of 11
Table 1: Summary of the Monte-Carlo simulation study.
s.d = 0.01 Model R2
adj AICc Akaike weights BIC resVar red. Chi2
L5 0.99999471 -156.22 0.0818 -156.35 0.00009933 0.9924
L4 0.99999471 -158.36 0.2389 -158.33 0.00009935 0.9930
L3 0.99999470 -160.20 0.5969 -160.33 0.00009959 0.9927
B5 0.99999258 -147.31 0.0010 -147.44 0.00013945 1.4739
B4 0.99975702 -57.72 0.0000 -57.69 0.00456696 42.5939
B3 0.99959911 -47.29 0.0000 -47.42 0.00734455 63.5805
W4 0.99853046 -10.89 0.0000 -10.85 0.02762048 282.3939
W3 0.99829856 -7.91 0.0000 -8.04 0.03336157 334.1353
baro5 0.99999471 -156.21 0.0814 -156.34 0.00009936 0.9927
s.d = 0.02 L5 0.99997869 -119.98 0.0774 -120.11 0.00040059 0.9946
L4 0.99997868 -122.13 0.2273 -122.10 0.00040068 0.9959
L3 0.99997871 -124.06 0.5954 -124.19 0.00040007 0.9957
B5 0.99997653 -117.49 0.0224 -117.62 0.00044108 1.1135
B4 0.99974038 -56.14 0.0000 -56.11 0.00487955 11.4098
B3 0.99958227 -46.30 0.0000 -46.43 0.0076527 16.6958
W4 0.99851513 -10.64 0.0000 -10.61 0.02790803 71.2971
W3 0.99828395 -7.71 0.0000 -7.84 0.03364791 84.1649
baro5 0.99997869 -119.98 0.0775 -120.11 0.00040044 0.9956
s.d. = 0.05 L5 0.99986676 -72.33 0.0765 -72.46 0.00250459 0.9897
L4 0.99986656 -74.44 0.2194 -74.41 0.00250829 0.9904
L3 0.99986662 -76.34 0.5674 -76.47 0.00250720 0.9882
B5 0.99986439 -71.87 0.0608 -72.00 0.00254924 1.0096
B4 0.99962966 -47.44 0.0000 -47.40 0.00696139 2.6343
B3 0.99946832 -40.44 0.0000 -40.57 0.00973888 3.4859
W4 0.99839915 -8.85 0.0000 -8.81 0.03009194 12.3020
W3 0.99817327 -6.21 0.0000 -6.34 0.03582530 14.3447
baro5 0.99986669 -72.32 0.0759 -72.45 0.00250592 0.9902
s.d. = 0.1 L5 0.99947371 -36.57 0.0742 -36.70 0.00989448 0.9984
L4 0.99947362 -38.73 0.2180 -38.70 0.00989607 0.9972
L3 0.99947374 -40.62 0.5618 -40.75 0.00989674 0.9972
B5 0.99947135 -36.46 0.0701 -36.59 0.00993888 1.0037
B4 0.99923746 -29.03 0.0017 -28.99 0.01433573 1.4052
B3 0.99907025 -26.35 0.0004 -26.48 0.01703305 1.6200
W4 0.99800791 -3.50 0.0000 -3.47 0.03745226 3.8282
W3 0.99779177 -1.55 0.0000 -1.68 0.04333951 4.3370
baro5 0.99947355 -36.56 0.0737 -36.69 0.00989740 0.9982
s.d. = 0.2 L5 0.99786138 -0.07 0.0675 -0.20 0.04025347 0.9948
L4 0.99785879 -2.18 0.1942 -2.15 0.04030142 0.9940
L3 0.99785563 -4.04 0.4930 -4.17 0.04035658 0.9928
B5 0.99785959 -0.05 0.0668 -0.18 0.04028754 0.9960Spiess and Neumeyer BMC Pharmacology 2010, 10:6
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decreasing. Even in the presence of relatively high noise
(s.d. = 0.4), at least for the simulation setup in this work,
R2
adj  would hardly drop below 0.99. Comparing the
Akaike weight of the models with the R2
adj values in Table
1 shows the strong discrepancy in scale changes of these
two measures when comparing a cohort of different
models.
However, differences in scale changes would be unim-
portant if the direction of change is always reciprocally
(i.e. a lower AICc always corresponding with a higher
R2adj). As can be deduced from Table 1, this is not always
the case. Using the averaged measures from the simula-
tions, R2adj and AICc did not always behave reciprocally.
For instance, at s.d. = 0.05, 0.2 and 0.4 the 'true' model L3
has a lower AICc than L5 (and ~ 8 times more weight of
evidence by Akaike weights), but R2adj values are also
lower in the fifth to eighth decimal place. Using R2adj for
model selection would therefore have resulted in a model
which is clearly not in favor based on Akaike weights.
On the averaged values, BIC essentially shows the same
characteristics as AICc. Interestingly, the residual vari-
ance is higher in the 'true ' model L3 than L5 for most
noise regimes (although also only in the third to eighth
decimal place), indicating this to be a relatively unfavor-
able measure. Likewise, the reduced chi-square exhibited
a tendency to be closest to unity for higher parameter
models (L4, L5, B5) with increasing noise, here also only
affected in the third decimal place.
To acquire more detailed insight into the performance
of the different measures in respect to the selection of the
best model and in dependence of different noise magni-
tudes, we selected the best model of each iteration by
each of the measures. This approach can reveal features
that are not evident when calculating the averaged mea-
sures of all simulations. We summarized the outcome of
this analysis as a heatmap display in Figure 4 and as
'model selection frequency' in Table 2. Within each image
plot, the selected models are shown with the same colour
coding as in Figures 1, 2 and 3. For the low (s.d. = 0.02)
and medium (s.d. = 0.1) setup, R2
adj, residual variance
(resVar) and reduced chi-square performed not opti-
mally, selecting the true model L3 only in 28-43% of the
iterations. Both measures exhibited a severe bias in the
selection of models with a higher number of parameters
(L4, L5, B5, baro5). It is interesting to note that although
R2
adj and the residual variance 'correct' against the num-
ber of parameters, there is no positive effect on the ability
to select the 'true' model. This may be due largely to the
setup in this work which features a relatively high sample
size (n = 26) compared to the number of parameters (p =
3-5) and leaves the denominator n - p in both measures
relatively unaffected. In contrast, both AICc and BIC per-
formed superior in the selection of the 'true' model L3 at
these magnitudes of noise with over 80% of all iterations,
but with a slight bias to models with a lower number of
parameters at medium noise. At high noise (s.d. = 0.4,
corresponding to 4% noise of the data range) the perfor-
mance of all measures decreased markedly, most proba-
bly from the effect of the simulated data losing the
s t r u c t u r a l  f e a t u r e s  t y p i c a l  o f  t h e  L 3  m o d e l  w h e n  h i g h
B4 0.99762513 0.49 0.0512 0.52 0.04470201 1.1027
B3 0.99740761 0.20 0.0592 0.06 0.04751535 1.1543
W4 0.99640798 11.41 0.0002 11.44 0.06760434 1.6764
W3 0.99625943 11.71 0.0002 11.58 0.07350697 1.8059
baro5 0.99786149 -0.07 0.0676 -0.20 0.04025146 0.9941
s.d. = 0.4 L5 0.99160836 35.58 0.0490 35.45 0.15887711 0.9987
L4 0.99157911 33.50 0.1387 33.53 0.15941969 0.9981
L3 0.99158878 31.58 0.3613 31.45 0.15928956 0.9980
B5 0.99154493 35.68 0.0466 35.55 0.15991031 1.0001
B4 0.99135309 34.16 0.0996 34.19 0.16370200 1.0242
B3 0.99098926 32.68 0.2084 32.55 0.16621846 1.0372
W4 0.99017401 37.58 0.0180 37.61 0.18602148 1.1663
W3 0.99028174 36.53 0.0305 36.40 0.19208006 1.1995
baro5 0.99159379 35.62 0.0480 35.49 0.15915529 0.9989
Six different magnitudes of gaussian noise (low: s.d. = 0.01, 0.02; medium: s.d. = 0.05, 0.1; high: s.d. = 0.2, 0.4) were added to the fitted data of 
a three-parameter log-logistic model (L3). Nine different sigmoidal models were fit by nonlinear least-squares to the perturbed data and 
different measures for the goodness of fit (see Materials & Methods) averaged after all 2000 iterations. From the AICc values, Akaike weights 
were calculated in order to obtain the weight of evidence of the models.
Table 1: Summary of the Monte-Carlo simulation study. (Continued)Spiess and Neumeyer BMC Pharmacology 2010, 10:6
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noise is added. Despite this negative trend, AICc and BIC
displayed increased performance even at high noise. The
two measures selected also a significant number of itera-
tions (about 40%) of other models with the same number
of parameters (B3, W3), which might be an indication for
a small bias to lower parametrized models. Consequently,
and based on the analysis of a sigmoidal nonlinear setup
as described here, we feel compelled to give the following
summary:
1) The use of highly inferior nonlinear models is
reflected only in the third or fourth decimal place of R2
and thus the description of single models when using R2
is not meaningful, as this measure tends to be uniformly
high when a set of models is inspected. This has also been
noted by others [20]. Additionally, R2 and even its 'bias-
corrected' counterpart R2adj are severely biased in favor
of models with more parameters when it comes to model
selection. The same accounts for the residual variance,
which is also commonly used. AICc and BIC do not
exhibit this bias and provide a much clearer picture and
improved performance when it comes to selecting the
'true' model. The Akaike weights are especially useful in
obtaining an overview of the weight of evidence of one
model over the other, which is impossible with the per se
high R2 values. This approach requires anyhow that it is
mandatory to supply several models in question.
2) In a background of low and medium experimental
noise, R2
adj and AICc selected different models with AICc
selecting the 'true model' twice as often (82.2% versus
43%). This finding emphasizes the importance of this
measure in nonlinear model selection. At a high noise
level rarely encountered in the modelling of pharmaco-
logical/biochemical data (4% of data range), AICc still
performed superior to R2
adj. These results tempt us to
conclude that the degree of freedom term  n - p in the
denominator of the residual variance and R2
adj is not suffi-
cient alone to compensate the effect of the number of
increasing parameters. The same seems to be the case for
the reduced chi-square, which is also frequently used for
model selection purposes.
In this work we show that R2 is an inappropriate mea-
sure when used in the field of nonlinear fitting. Efforts
have been made to develop R2-like measures for the most
common nonlinear regression models [21], but here we
focused on the inadequateness of its use by using a data
perturbation approach and comparing its performance in
Figure 3 Analysis of adjusted R2 and corrected AIC of nine different sigmoidal models on fitted data from a three-parameter log-logistic 
model (L3). Three different magnitudes of homoscedastic gaussian noise (low: 0.02; medium: 0.1; high: 0.4) were added to the fitted data (2000 sim-
ulations), each of the nine sigmoidal model fit by nonlinear least-squares and the two measures collected for each simulation. Finally, the measures 
were averaged and displayed as point graphs. Upper panel: AICc, lower panel: R2
adj. Descriptions for the abbreviated models can be found under For-
mulas 1-9. Coefficients of variation for all simulations were below 5% and hence omitted. More detailed data for the measures can be found in Table 1.
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comparison to AICc, BIC, residual variance and reduced
chi-square. Model selection in nonlinear statistical litera-
ture is usually divided into the frequentist methods, for
example F-tests on the residual variance that are
restricted to nested models [13], or measures from infor-
mation theory such as AIC which are often used to com-
pare non-nested models. Indeed, it has been shown that
the latter approach can often perform better than F-tests
[22]. In the field of biochemical and pharmacological lit-
erature there is a reasonably high occurrence in the use of
R2 as the basis of arguing against or in favor of a certain
model. As a result from this work, we would like to advo-
cate that R2  s h o u l d  n o t  b e  r e p o r t e d  o r  d e m a n d e d  i n
phamacological/biochemical literature when discussing
nonlinear data analysis. Authors as well as reviewers
should be aware that demonstrating the validity of single
nonlinear models by using solely R2 is not state-of-the-art
and should be replaced or supplemented by AIC/AICc/
BIC values (or their corresponding weights of evidence) of
several possible models that are in question. The latter
Table 2: Model selection frequency for the different measures of goodness-of-fit.
Model R2adj AICc BIC resVar red. Chi2
s.d. = 0.02 L5 228 40 41 231 227
L4 341 170 154 347 261
L3 867 1648 1660 857 567
B5 305 90 91 304 689
B4
B3
W4
W3
baro5 259 52 54 261 256
L3 [%] 43.4 82.4 83.0 42.9 28.4
s.d. = 0.1 L5 124 10 10 122 118
L4 349 161 145 365 288
L3 958 1668 1684 939 576
B5 279 30 30 283 308
B4 35 53 51 34 361
B3 5 43 44 6 144
W4
W3
baro5 250 35 36 251 205
L3 [%] 47.9 83.4 84.2 47.0 28.8
s.d. = 0.4 L5 42 5 6 43 69
L4 234 72 65 243 187
L3 698 982 989 667 374
B5 55 3 3 61 67
B4 257 81 76 194 208
B3 303 575 582 406 335
W4 51 46 43 89 305
W3 221 226 226 145 357
baro5 139 10 10 152 98
L3 [%] 34.9 49.1 49.5 33.4 18.7
Same setup as in Table 1 but summarizing the model selection for each iteration and each measure by selection frequency. A percentage of 
selecting the 'true' model L3 is given as a summary.Spiess and Neumeyer BMC Pharmacology 2010, 10:6
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Page 10 of 11
will give the dedicated reader the possibility to obtain
information about how much a certain model is in favor
over others, a feature that will not be evident by minor
changes in R2 which tends to be uniformly high and is
rarely affected more than in the third or fourth decimal
place.
Conclusions
Although frequently being used in the present pharmoco-
logical/biochemical literature for describing the validity
of a nonlinear fit, R2 is an unfavorable measure that is
rarely affected more than in the third or fourth decimal
place, even in scenarios with highly inferior models. Our
Monte Carlo simulations have shown that AIC, AICc or
BIC perform significantly better in this respect so that
authors as well as reviewers should be aware of this issue
and refrain from using or asking for R2 values when non-
linear models are under investigation.
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Figure 4 Analysis of model selection bias between for different measures of goodness-of-fit. Three different magnitudes of homoscedastic 
gaussian noise (0.02%; 0.1%; 0.4%) were added to the fitted data of model L3. The nine different sigmoidal models were fit and the different measures 
for goodness-of-fit collected at each iteration. The best model was selected for each measure and displayed for all iterations as a coloured selection 
heatmap. Light green reflects the 'true' model L3.
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